ITIL-306 is under clinical development by Instil Bio and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase I drugs for Endometrial Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ITIL-306’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ITIL-306 is under development for the treatment of gynecological cancers, non-small cell lung cancer, epithelial ovarian cancer, high grade serous, endometrioid, or clear cell epithelial carcinoma of fallopian tube, or peritoneum, lung adenocarcinoma, papillary renal cell carcinoma and solid tumors. The therapeutic candidate comprises tumor infiltrating lymphocytes (TIL) genetically engineered to express a Co-Stimulatory Antigen Receptor (CoStAR) molecule targeting folate receptor alpha (FOLR1). It is administered through parenteral route.
Instil Bio overview
Instil Bio is a biopharmaceutical company that develops optimized and genetically-engineered tumor infiltrating lymphocytes (TIL) for the treatment of cancer. It is investigating its lead product candidate ITIL-168 against melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer. The company is also evaluating ITIL-306 drug to treat gynaecological malignancies among other tumors. Instil Bio utilizes its proprietary TIL manufacturing platform to develop its products. The company operates research and cell therapy manufacturing facilities in Los Angeles, the US and Manchester, the UK. Instil Bio is headquartered in Dallas, Texas, the US.
For a complete picture of ITIL-306’s drug-specific PTSR and LoA scores, buy the report here.